AK-2017

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameAK-2017

Drug Alias Name重组人生长激素-Fc融合蛋白（安科生物）AK2017AK-2017

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionGrowth hormone receptor agonists

TargetsGrowth hormone receptor

Therapy Area/IndicationsGrowth hormone deficiencyIdiopathic short stature

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesAnhui Anke Biotechnology (Group) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAnhui Anke Biotechnology (Group) Co Ltd

Inactive CompaniesN/A

Active IndicationsGrowth hormone deficiencyIdiopathic short stature

Inactive IndicationsN/A

Other Information

ATC CodeN/A